Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
11/2005
11/23/2005EP1039930B1 ADJUVANTED VACCINE COMPRISING AN ANTIGEN FROM STREPTOCOCCUS PNEUMONIAE AND A CpG OLIGONUCLEOTIDE
11/23/2005EP1001797B9 Soya extract, process for its preparation and pharmaceutical composition
11/23/2005EP0988309B1 C-4''-substituted macrolide derivatives
11/23/2005EP0906088B1 Liposomal antineoplaston therapies with markedly improved antineoplastic activity
11/23/2005EP0837939B1 Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods
11/23/2005EP0792347B1 Methods for producing enhanced antigenic helicobacter sp. and vaccines comprising same
11/23/2005EP0781344B1 Novel implant and novel vector for the treatment of acquired diseases
11/23/2005EP0778780B1 Capsular polysaccharide immunomodulator
11/23/2005EP0662128B1 Methods and compositions for controlling translation of hcv proteins
11/23/2005CN1701116A Probiotic bacterium: lactobacillus fermentum
11/23/2005CN1701061A New compounds for the inhibition of rotamases and use thereof
11/23/2005CN1700934A Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols
11/23/2005CN1699385A Crystal form of adefovir dipivoxil
11/23/2005CN1698601A Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use
11/23/2005CN1228145C Device and method for coating high-efficient ingredient on plants, application thereof and finished product
11/23/2005CN1228088C Cross-breed vaccine carrier and its application
11/23/2005CN1228087C Medicinal preparation and its prepn. and application
11/23/2005CN1228085C Forest cerebritis purifying vaccine
11/23/2005CN1228081C Combination of medicinal preparation of having antivirus function
11/23/2005CN1228077C Chinese drugs for treating Hepatitis B and AIDS
11/23/2005CN1228070C Red sage root-astragalus root particles for liver softening
11/23/2005CN1228063C Medicine for treating liver disease
11/23/2005CN1228062C Medicine for treating liver disease
11/23/2005CN1228057C Compound of solanesol and its preparing process
11/23/2005CN1227977C Composition of N-phenyl-N'-benzoyl carbamide derivant and stem protein compound for preventing vermin
11/22/2005US6967245 Ucp5
11/22/2005US6967220 antibiotics; treating respiratory system disorders; n-hydroxy benzyl formamide derivatives
11/22/2005US6967214 Inhibitors of IMPDH enzyme
11/22/2005US6967205 Compounds with antibacterial and antiparasitic properties
11/22/2005US6967197 Also used in production of tumor necrosis factor alpha
11/22/2005US6967097 Nucleotide sequences coding enzymatic polypeptide for use in the treatment of viral diseases
11/22/2005US6967090 Nucleic acid and protein sequences of bovine epidermal growth factor
11/22/2005US6967023 solidifying agent consists of a long chain fatty alcohol having at least 15 carbon atoms in its backbone and a fatty acid having at least 18 carbons in its backbone; carrier is semi-solid at rest and liquefies upon application of shear forces
11/22/2005CA2277100C Cyclic sulfone derivatives
11/22/2005CA2267639C Synthetic hpv16 virus-like particles
11/22/2005CA2249336C Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
11/22/2005CA2184101C Carbapenem derivatives
11/22/2005CA2171531C Multiple branch peptide constructions for use against hiv
11/22/2005CA2068066C Herpesvirus particles and vaccine
11/17/2005WO2005108581A1 Recombinant virus vector for gene introduction in lymphocyte
11/17/2005WO2005108418A1 Compounds for specific viral target
11/17/2005WO2005108400A1 Pyridoquinazoline derivatives having heterobicyclic substituents
11/17/2005WO2005107769A1 Oral flora-improving agent, antibacterial agent and growth promoter
11/17/2005WO2005107748A2 Method of tonic treatment with oxyphenbutazone derivatives
11/17/2005WO2005107731A1 Remedies containing vitamin k2 as the active ingredient
11/17/2005WO2005065063A3 Use of the mushroom agaricus blazei murill for the production of medicaments suitable for treating infections and allergies
11/17/2005WO2004108945A3 Oligonucleotide modulation of cell adhesion
11/17/2005WO2003068941A3 Modulation of immune response by non-peptide binding stress response polypeptides
11/17/2005US20050256315 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
11/17/2005US20050256299 Vaccines
11/17/2005US20050256298 Method for preparing free flow resin
11/17/2005US20050256148 Topoisomerase I inhibitors; improved stability, water solubility, toxicity; anticancer agents; camptothecins bearing an oxime group in position 7; 7-tert-butoxyiminomethyl-20-O-(4-trimethyl-ammonium-3-hydroxy)butanoyl-camptothecin bromide; parasitic or viral infections
11/17/2005US20050256142 New purine derivatives
11/17/2005US20050256136 1-[2-(3-Ethyl-ureido)-3H-benzoimidazol-5-yl]-1H-imiazole-4-carboxylic acid methyl ester; bacteriostatic antibiotic; decrease antibiotic resistance of bacterial organisms; new class of compounds for bacterial infections
11/17/2005US20050256126 for treatment of microbial infections; potent inhibitors of (bMAP) bacterial aminopeptidase
11/17/2005US20050256122 Substituted pyridazinones
11/17/2005US20050256093 Branched polyamine steroid derivatives
11/17/2005US20050256090 Comprises as an active ingredient a sulphostin-related compound such as 3(S)-amino-1-((S)-amino(sulfoamino)-phosphinyl)-2-piperidone
11/17/2005US20050256079 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
11/17/2005US20050256063 Crystal forms of azithromycin
11/17/2005US20050256062 A tablet of a crystalline form of azithromycin sesquihydrate or crystalline azithromycin monohydrate hemi-isopropanol solvate and a carrier or diluent; nuclear magnetic resonance spectrum analysis; bactericides; antiprotozoa agents; infections of humans, mammals, birds, fish; drug resistance
11/17/2005US20050256060 Mono-and disaccharide derivatives
11/17/2005US20050256051 Nuclear receptor-mediated introduction of a PNA into cell nuclei
11/17/2005US20050256037 Antibacterial amide macrocyles
11/17/2005US20050255549 IRAK-4: compositions and methods of use
11/17/2005US20050255454 Administering antigens capable of causing specific immune reaction(s) directed against an infectious agent and/or cells infected with the infectious agent, and decreasing a different specific immune reaction direct towards the infectious agent, infected cells and/or uninfected cells; immunotherapy
11/17/2005US20050255156 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
11/17/2005US20050255125 Streptococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine
11/17/2005US20050255124 HCV E1E2 vaccine compositions
11/17/2005US20050255101 Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
11/17/2005DE10392697T5 Herstellung und Standardisierung von immunmodulierenden Peptid-verknüpften Glucanen mit nachweisbarer oraler Resorbierbarkeit aus Coriolus Versicolor Preparation and standardization of immunomodulating peptide-linked glucans with detectable oral absorbability from Coriolus Versicolor
11/17/2005DE10335061B4 Verfahren zur Herstellung von OH-geschützten [4-(2,6-damino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol-Derivaten Process for preparing OH-protected [4- (2,6-Damino-9H-purin-9-yl) -1,3-dioxolan-2-yl] methanol derivatives
11/17/2005CA2777216A1 Process for preparing atazanavir bisulfate and novel forms
11/17/2005CA2566228A1 Method of tonic treatment with oxyphenbutazone derivatives
11/17/2005CA2565658A1 Compounds for specific viral target
11/17/2005CA2565509A1 Recombinant virus vector for gene introduction in lymphocyte
11/17/2005CA2563400A1 Medicament for the treatment of fungal infections, particularly aspergillosis
11/16/2005EP1595959A1 Method for enhancing efficacy of preparation of monoclonal antibody
11/16/2005EP1595890A2 Synthetic peptide inhibitors of HIV transmission
11/16/2005EP1595539A1 Drug for reducing side effects in ribavirin interferon combination therapy
11/16/2005EP1595537A1 Buccal cavity treatment composition and corresponding uses thereof
11/16/2005EP1595536A1 Pharmaceuticals comprising shikonins as active constituent
11/16/2005EP1594978A2 Assay for the identification of protein sic inhibitors
11/16/2005EP1594976A2 ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ACTIVITY AGAINST RESISTANT HIV STRAINS
11/16/2005EP1594898A2 Glycosylated specificity exchangers
11/16/2005EP1594870A1 Substituted indolepyridinium as anti-infective compounds
11/16/2005EP1594866A1 Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives
11/16/2005EP1594865A2 Antibacterial agents
11/16/2005EP1594852A1 Oxazolidinone derivatives as antimicrobials
11/16/2005EP1594828A1 Antimicrobial trinervitane derivatives
11/16/2005EP1594560A2 Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
11/16/2005EP1594512A2 Compounds for the treatment of viral infection
11/16/2005EP1594500A1 Treatment of bacterial diseases of the respiratory organs by locally applying fluoroquinolones
11/16/2005EP1594495A1 Oxazolidinone derivates n-substituted by a tricyclic ring, for use as antibacterial agents
11/16/2005EP1594494A1 Oxazolidinone derivatives n-substituted by a bicyclic ring, for use as antibacterial agents
11/16/2005EP1594492A2 Novel inhibitors of formation of advanced glycation endproducts (ages)
11/16/2005EP1594491A1 Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections
11/16/2005EP1594444A2 Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
11/16/2005EP1594439A2 REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS
11/16/2005EP1594435A2 Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
1 ... 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 ... 1798